ClinicalTrials.gg
RecruitingNCT05458544LUCIDAUpdated Apr 29, 2024

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

A Phase 1/2 interventional study of [177Lu]Ludotadipep 3.7 GBq in Metastatic Castration-resistant Prostate Cancer, sponsored by FutureChem. Recruiting at 4 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by FutureChem · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Lutetium-177 in Prostatic Neoplasms — 8 open to participants now, 10 under way, none of them phase 3. Lutetium-177 · Prostatic Neoplasms.

Planned enrollment
9th of 14
26 · median 31
Started
2022
with 1 other
Phase 1/2
4 of 14
3 open now
Registered
2nd of 14
by date
Lead sponsor
1 of 14
FutureChem

Among the 14 studies testing Lutetium-177 in Prostatic Neoplasms, this one is the 9th largest by planned enrollment, is one of 2 that started in 2022, is one of 4 in phase 1/2, and was the 2nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 14 studies testing Lutetium-177 in Prostatic Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Lutetium-177

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Lutetium-177 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Phase 1: The objective of the Phase 1 part of the clinical trial is to verify safety and tolerability (dose-limiting toxicity [DLT], maximum tolerated dose [MTD]) of a single 3.7 Giga-Becquerel (GBq) dose with the potential for one dose level de-escalation to 2.775 GBq if necessary, to determine the recommended [177Lu]Ludotadipep dose for use in the Phase 2a part of the trial.

Phase 2a: The objective of the Phase 2a part of the trial is to evaluate safety and efficacy for repeated administration of the recommended [177Lu]Ludotadipep dose. The Recommended Phase 2 dose (RP2D) will be based on the study results from the Phase 1 trial in South Korea upon consultation with the FDA.

Read the detailed description

Phase 1:

The patient will attend a Screening visit (-28 to -1 days) prior to study treatment, where it will be determined if the patient is eligible to, and consents to, participate in the trial based on the inclusion/exclusion criteria. [Ga-68]PSMA-11 positron emission tomography (PET)/CT scan will be performed at screening.

Patients who are finally registered for trial participation will be injected with a single dose of [177Lu]Ludotadipep. Ice packs and other cooling therapies will be applied to the major salivary glands from 30 minutes before the administration of [177Lu]Ludotadipep to 60 minutes after the administration to prevent side effects such as sialadenitis. Amino acid solution will be administered slowly intravenously for renal protection over approximately 4 hours from 30 minutes before treatment to 3.5 hours after treatment. 500 mL of 0.9% sodium chloride (NaCl) will be administered slowly intravenously for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.

Adverse events and DLTs will be assessed continuously for the duration of the 8 [±1] week study period. Other measurements, corresponding to secondary outcomes, are detailed in the Schedule of Assessments and include concomitant medications, laboratory tests, physical examination, vital signs, Eastern cooperative oncology group performance status (ECOG PS), imaging (positron emission tomography-computed tomography [PET/CT], bone scan and Whole Body Scan (WBS)). Follow-up will occur at scheduled visits 1, 2, 4 and 8 weeks after investigational product (IP) administration.

Patients who show a clinical response and who the PI considers will likely benefit from retreatment can be so treated after consultation and agreement of the medical monitor and the sponsor.

Phase 2a:

The patient will attend a Screening visit (-28 to -1 days) prior to treatment with IP, where it will be determined if the patient is eligible to, and consents to, participate in the trial based on the inclusion/exclusion criteria. [Ga-68]PSMA-11 PET/CT and [F-18]FDG-PET scans will be performed at screening.

Patients who are finally registered for trial participation will be injected with a single dose of [177Lu]Ludotadipep. Ice packs and other cooling therapies will be applied to the major salivary glands 30 minutes before and up to 60 minutes after the administration of [177Lu]Ludotadipep to prevent side effects such as sialadenitis. Amino acid solution will be administered slowly intravenously for renal protection over approximately 4 hours from 30 minutes before treatment to 3.5 hours after treatment. 500 mL of 0.9% NaCl will be administered slowly intravenously for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment. WBS or single photon emission computed tomography (SPECT) images will be obtained 24 hours after each administration and Day 7, and AE information will also be captured. Other measurements are detailed in the Schedule of Assessments.

Patients will receive [177Lu]Ludotadipep every 8 [±1] weeks (4 to 6 times).

Patients will be contacted by phone 2 weeks after the first administration for a safety check-up. Four and six weeks after each administration the patient will attend the clinic for a follow-up visit. The following assessments will be performed:

  • PSA and other laboratory blood tests (4 and 6 weeks)
  • AEs (4 and 6 weeks)
  • Urinalysis, physical examination, vital signs, ECOG PS, EORTC QLQ-C30 and Pain Response questionnaires (4 weeks only) The decision on whether to proceed with additional administrations will be determined every 6 weeks after administration of the IP, based on investigator's assessment of tolerability. If a patient does not progress to the next dose administration at 8 weeks, a PSA blood sample will be taken.

A tumor response assessment by CT and bone scan, and additional [Ga-68]PSMA-11 PET/CT and FDG-PET scans will be conducted at end of treatment (EOT). All follow up assessments are detailed in the Schedule of Assessments.

All patients will have long term follow-up every 6 months for 2 years after the last dose of IP unless there is death, withdrawal of consent, or loss to follow-up. Patients who are alive at >2 years after the last dose of IP, unless there is death, withdrawal of consent, or loss to follow-up will be offered participation in a long-term follow-up protocol for up to 10 years. In the long-term survival follow-up, the long-term outcome of the known serious risk of myelosuppression, renal failure, xerostomia, xerophthalmia, and their complications; the potential serious signals of secondary malignancies including myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML); and other serious adverse reactions, will be monitored.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet the following criteria in order to be included in both the Phase 1 and Phase 2a parts of the trial:

  1. Male and ≥ 18 years
  2. or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features at initial diagnosis
  3. Disease progression on any one of the following: prior enzalutamide, abiraterone, apalutamide or related agent therapy as defined by meeting at least one of the following criteria per the investigator in accordance with the Prostate Cancer Working Group 3 (PCWG3) criteria [Scher et al, 2016]:

    1. PSA progression as defined by a minimum of two rising PSA levels at least 1 week apart, ideally three successive measurements
    2. Soft tissue disease progression defined as >20% increase in sum of diameters of all target lesions based on sum of diameters since treatment started or the appearance of 1 or more new lesions by 1.1
    3. Bone disease progression defined by two or more new lesions on bone scan
  4. Serum testosterone level \< 50 ng/dL (\< 0.5 ng/mL, \< 1.7 nmol/L). Patients may have ongoing androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) "super-agonist" or antagonist, and/or be surgically or medically castrated.
  5. Patients must have PSMA positive lesions. These are defined as having Ga 68-PSMA-11 uptake greater than that of liver parenchyma in one or more lesions of any size in any organ system. PSMA-negative lesions are defined as having PSMA uptake equal to or lower than that of liver parenchyma in any lymph node with a short axis of at least 2.5 cm, in any metastatic solid-organ lesions with a short axis of at least 1.0 cm, or in any metastatic bone lesion with a soft-tissue component of at least 1.0 cm in the short axis.
  6. Patients receiving bisphosphonate therapy must have been on stable doses for at least 4 weeks prior to Day 1
  7. Patients who have received a taxane or are ineligible or choose not to receive taxane-based chemotherapy based on personal preference or physician opinion. Examples of conditions that could make a patient ineligible or refuse to receive taxane-based chemotherapy include the following:

    1. Poor performance status
    2. Prior intolerance to cytotoxic agents
    3. Other serious medical conditions such as symptomatic peripheral neuropathy (CTCAE) Grade 2 or higher; or cardiovascular disease per the Investigator
  8. PS of 0 to 2 for Phase 1 and 0 to 1 for Phase 2a
  9. Estimated of at least 3 months for Phase 1 and 6 months for Phase 2a as determined by the Investigator.
  10. For patients who have partners of , the partner and/or patient must use a method of with adequate barrier protection, deemed acceptable by the principal investigator during the study and for 3 months after last study drug administration.
  11. Able and willing to provide signed and comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria (applies to both Phase 1 and Phase 2a):

  1. Impaired organ function as evidenced by the following laboratory values at Screening:

    1. \< 1500/μL
    2. count \< 100,000/μL
    3. \< 9.0 g/dL Note: the patient cannot have received blood transfusion or growth factor support in the 2 weeks prior to screening laboratory hematology assessments.
    4. Albumin \< 3.0 g/dL (30 g/L)
    5. Total > 2 x (ULN) unless in instances of known or suspected Gilbert's disease
    6. (AST) or alanine aminotransferase (ALT) > 2.5 x ULN
    7. Calculated \< 60 mL/min (Cockroft-Gault equation), or currently on renal dialysis
  2. corrected for heart rate (QTcF) > 470 msec
  3. Sjogren's syndrome
  4. Known or suspected or active
  5. History of other within the previous 3 years, except basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer
  6. History of active thromboembolism within the last 3 months of Day 1
  7. Serious persistent infection within 14 days prior to Day 1
  8. If the patient is known to have a positive polymerase chain reaction (PCR) test for active COVID-19 infection or signs or symptoms consistent with COVID-19, in the absence of a positive PCR test, within 5 days from date of consent
  9. Patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completing the study
  10. History of congestive heart failure (NYHA) class III or IV, uncontrolled hypertension or evidence of coronary artery disease (including a myocardial infarction) within the previous 6 months from date of consent
  11. Patients who received any anti-tumor therapy within 4 weeks of Day 1, with the exception of abiraterone, enzalutamide or apalutamide, GnRH therapy and non-radioactive bone-targeted agents
  12. Superscan as evidenced on baseline bone scan
  13. Treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 within 6 months prior to Day 1
  14. Prior hemi-body irradiation
  15. Prior PSMA-targeted radioligand therapy
  16. Major surgery within 4 weeks of Day 1
  17. Prior systemic beta-emitting bone-seeking radioisotopes
  18. Radiation therapy for treatment of prostate cancer within 4 weeks of Day 1
  19. Use of anticoagulants within 3 months prior to Day 1 for patients with a history of thromboembolic conditions. Note: Patients receiving anticoagulants for atrial fibrillation are eligible for the study so long as they are on a stable dose of anticoagulants
  20. Prior use of any herbal products known to decrease PSA levels (e.g., PC-SPES [prostate cancer hope - dietary supplement] or saw palmetto) within 30 days prior to Day 1
  21. Planned initiation of alternative therapy for prostate cancer, therapy, or participation in clinical trials during the study
  22. Known history of (HIV) or C infection:

    1. HIV infected patients who are healthy and have a low risk of Acquired Immune Deficiency Syndrome (AIDS)-related outcomes will be included.
    2. Patients with a history of hepatitis B or C will be allowed to enrol if hepatitis B virus (HBV) DNA or virus (HCV) RNA are undetectable. At this early stage of development, about the main concern is the potential for re-activation or worsening of HBV or HCV from the effect of radiation on lymphocyte function.
  23. Vulnerable patients (the investigator involved in the study or his/her family, research staff or students of the investigator involved in the study)
  24. Implantation of investigational medical device within 4 weeks of Day 1 or current enrolment in oncologic investigational drug or device study
  25. Use of investigational drugs within 4 weeks or less than 5 half-lives of Day 1
  26. Patients are excluded if treatment other than the treatment provided in this study is determined more appropriate as determined by the investigator based on the patient and disease characteristics
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    [177Lu]Ludotadipep 3.7 GBq

    If investigators observed one or no DLT in 6 patients at the 3.7 GBq dose level, the study can advance to the Phase 2a part of the trial after the safety review committee (SRC) review.

    Drug: [177Lu]Ludotadipep 3.7 GBq

Interventions

  • Phase 1: Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep * Test article code/name: \[177Lu\]Ludotadipep * Administration route: intravenous injection * Total dose strength: 3.7 GBq * Dosage form: solution for injection Phase 2a: Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times) * Test article code/name: \[177Lu\]Ludotadipep * Administration route: intravenous injection * Total dose strength: 4 to 6 x 3.7 GBq * Dosage form: solution for injection

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT) with a single fixed dose of [177Lu]Ludotadipep during the first cycle (8 [±1] weeks) (Phase 1)

    Determination of Maximum Tolerated Dose (MTD)

    Time frame: Single dose and 8 weeks follow up (Screening up to 28 days)

  2. Objective Response Rate (Phase 2a)

    Complete Response \[CR\] Rate + Partial Response \[PR\] Rate

    Time frame: up to 40 weeks (4 to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)

Secondary outcomes

  1. Safety assessments (Phase 1)

    Safety assessments will include the recording of AEs from the time of signing the informed consent form (ICF), laboratory tests, electrocardiograph (ECG), vital signs, physical examinations and Eastern Cooperative Oncology Group Performance Status (ECOG PS).

    Time frame: Single dose and 8 weeks follow up (Screening up to 28 days)

  2. Whole-body absorbed dose (Phase 1)

    Whole-body absorbed dose of \[177Lu\]Ludotadipep biodistribution parameters will be performed as follows: 1. Analysis will be conducted on data collected approximately 2 hours, 24 hours, 48 hours and 7 days after injection with IP using the obtained WBS images. 2. Aspects on biodistribution will be confirmed in WBS images. 3. A chart will be prepared with confirmed values for each organ, and a descriptive and comparative analysis will be conducted for the changes over time.

    Time frame: Single dose and 8 weeks follow up (Screening up to 28 days)

  3. Biodistribution: assessment of the absorption (uptake) into the blood, lungs, liver, spleen, pancreas, kidneys, muscle, stomach, and tumor based on the level obtained from whole body scan (WBS) 2 hours, 24 hours, 48 hours, and 7 days post-dose (Phase 1)

    The assessment of \[177Lu\]Ludotadipep biodistribution parameters will be performed as follows: 1. Analysis will be conducted on data collected approximately 2 hours, 24 hours, 48 hours and 7 days after injection with IP using the obtained WBS images. 2. Aspects on biodistribution will be confirmed in WBS images. 3. A chart will be prepared with confirmed values for each organ, and a descriptive and comparative analysis will be conducted for the changes over time.

    Time frame: Single dose and 8 weeks follow up (Screening up to 28 days)

  4. Disease Control Rate (Phase 2a)

    Disease Control Rate (DCR) = Complete Response Rate (CR) + Partial Response Rate (PR) + Stable Disease Rate (SD)

    Time frame: up to 40 weeks (4 to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)

  5. Safety assessments (Phase 2a)

    Safety assessments will include the recording of Adverse event (AEs) from the time of signing the Informed consent form (ICF), laboratory tests, Electrocardiograph (ECG), vital signs, physical examinations and Eastern cooperative oncology group performance status (ECOG PS).

    Time frame: up to 40 weeks (4 to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)

  6. Prostate Specific Antigen Response Rate (PSA RR) (Phase 2a)

    Defined as the proportion of participants with a PSA reduction of ≥ 50% from baseline

    Time frame: up to 40 weeks (4 to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)

  7. Tumor response rate (Phase 2a)

    Defined as the proportion of participants with a confirmed CR or PR divided by the total number of participants (using Response Evaluation Criteria in Solid Tumors 1.1 \[RECIST 1.1\])

    Time frame: up to 40 weeks (4 to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)

  8. Pain response rate (Phase 2a)

    Defined as: ≥2 point reduction in Present Pain Intensity Scale (PPI) score from baseline with no increase in analgesic score; and/or ≥50% decrease in analgesic score with no increase in PPI using the Short Form McGill Questionnaire (SF-MPQ)

    Time frame: up to 40 weeks (4 to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)

  9. European Organization for Research and Treatment of Cancer quality of life (EORTC QLQ-C30) questionnaire (Phase 2a)

    The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.

    Time frame: up to 40 weeks (4 to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)

  10. Time to death for any reason (Overall Survival [OS]) (Phase 2a)

    Defined as time from initiation to death of any cause

    Time frame: up to 40 weeks (4 to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)

07

Study locations

2 of 4 sites recruiting
  • VA Greater Los Angeles Healthcare System,Cancer Center Research
    Los Angeles, California 90073, United States
    Recruiting
    • Yuxin Li, MD · Contact
  • University of Maryland
    Baltimore, Maryland 20742, United States
    Not yet recruiting
    • Arif Hussain, MD · Contact
  • Chesapeake Urology Research Associates
    Towson, Maryland 21144, United States
    Not yet recruiting
    • Ronald Tutrone, MD · Contact
  • Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center)
    Gettysburg, Pennsylvania 17325, United States
    Recruiting
    • Satish A Shah, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Jun 2025, 33 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 33 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2022
First posted
Jul 14, 2022
StartActual
Sep 1, 2022
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05458544
Lead sponsor
FutureChem
Responsible party
Sponsor
First posted
Jul 14, 2022
Start date
Sep 1, 2022
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Apr 29, 2024

Study contacts

Chansoo Park, Ph.D
Contact
chansoo.park@futurechem.co.kr
+82-70-5066-2479
Jeffry Chen, MSc
Contact
jchen@linicalamericas.com
+1-772-208-7044
Arif Hussain, MD
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion